It operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.
Sales run at $72.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 58 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $113.9M against $72.7M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, IPVA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: IPVA is a high-risk stock — not yet profitable, and its future rides on its product catching on.